Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

NCT03601507 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Novartis has chosen to withdraw support for this trial

Conditions

CDKN2A-p16 Positive
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7
Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions

DRUG: Alpelisib
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacodynamic Study
PROCEDURE: Therapeutic Conventional Surgery

Sponsor

University of Arizona

Collaborators

[object Object]